Author: Sandra De Meyer; Denisa Bojkova; Jindrich Cinati; Ellen Van Damme; Christophe Buyck; Marnix Van Loock; Brian Woodfall; Sandra Ciesek
Title: Lack of Antiviral Activity of Darunavir against SARS-CoV-2 Document date: 2020_4_8
ID: 679qfp2s_6
Snippet: In this paper, the antiviral activity of DRV against SARS-CoV-2 was investigated in an in vitro model at clinically relevant concentrations. When DRV/c is taken at the indicated once-daily dose, the median trough plasma concentration of DRV was 3.4 µM (1875 ng/mL). (6) . This cell culture assay was shown to be suitable for antiviral assays. Productive viral infection takes place in this model with the number of SARS-CoV RNA molecules increasing .....
Document: In this paper, the antiviral activity of DRV against SARS-CoV-2 was investigated in an in vitro model at clinically relevant concentrations. When DRV/c is taken at the indicated once-daily dose, the median trough plasma concentration of DRV was 3.4 µM (1875 ng/mL). (6) . This cell culture assay was shown to be suitable for antiviral assays. Productive viral infection takes place in this model with the number of SARS-CoV RNA molecules increasing continuously after infection, indicating that the virus undergoes full replicatory cycles (12) . Remdesivir (GS-5734), a nucleotide analog initially developed for Ebola virus disease, has shown to inhibit SARS-CoV-2 replication in vitro with an EC 50 equal to 0,770 µM (13) and was therefore used as a positive control.
Search related documents:
Co phrase search for related documents- antiviral activity and cell culture assay: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- antiviral activity and daily dose: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- antiviral activity and DRV antiviral activity: 1, 2, 3, 4
- antiviral activity and Ebola virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69
- antiviral activity and Ebola virus disease: 1, 2, 3, 4, 5, 6, 7, 8, 9
- antiviral activity and nucleotide analog: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- antiviral activity and plasma concentration: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- antiviral activity and positive control: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
- antiviral activity and SARS DRV antiviral activity: 1, 2, 3
- antiviral activity and SARS replication: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- antiviral activity and SARS replication inhibit: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- antiviral activity and viral infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76
- antiviral activity and vitro model: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- antiviral assay and cell culture: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
- antiviral assay and cell culture assay: 1, 2, 3, 4, 5, 6, 7, 8, 9
- antiviral assay and Ebola virus: 1, 2, 3
- antiviral assay and positive control: 1, 2, 3
- antiviral assay and SARS replication: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- antiviral assay and viral infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
Co phrase search for related documents, hyperlinks ordered by date